Profile data is unavailable for this security.
About the company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-93.72m
- Incorporated2012
- Employees28.00
- LocationViking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 704-4660
- Fax+1 (302) 636-5454
- Websitehttps://vikingtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.56bn | 423.00 | -- | -- | -- | 1,481.39 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.64bn | 373.00 | 18.32 | 31.68 | 14.06 | 6.53 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 6.10bn | 105.00 | -- | 137.90 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.32bn | 1.31k | 33.54 | 3.01 | 27.44 | 3.42 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.32bn | 411.00 | -- | 3.66 | -- | 1,385.00 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.61bn | 645.00 | -- | 21.27 | -- | 23.42 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.63bn | 2.80k | 21.71 | 1.79 | 6.78 | 1.73 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 6.87bn | 28.00 | -- | 7.35 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.10bn | 610.00 | -- | 10.93 | -- | 13.81 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 7.29bn | 1.80k | -- | 6.27 | -- | 21.28 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.42bn | 355.00 | -- | 13.13 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.59bn | 420.00 | 40.45 | -- | 32.08 | 4.12 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 7.65bn | 254.00 | -- | 3.85 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Roivant Sciences Ltd | 124.80m | 4.35bn | 7.65bn | 845.00 | 2.04 | 1.40 | 1.80 | 61.33 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Viking Therapeutics Inc's reporting currency: US Dollar USD
40.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 16.22m | 14.84% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.52m | 6.88% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.73m | 6.16% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 3.59m | 3.28% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.33m | 3.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.33m | 2.13% |
| AllianceBernstein LPas of 31 Mar 2024 | 1.56m | 1.43% |
| Pictet Asset Management SAas of 31 Mar 2024 | 1.38m | 1.26% |
| Viking Global Investors LPas of 31 Mar 2024 | 1.09m | 1.00% |
| Voya Investment Management Co. LLCas of 31 Mar 2024 | 1.07m | 0.98% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
